A nuclear complex of rictor and insulin receptor substrate-2 is associated with albuminuria in diabetic mice

Metabolic Syndrome and Related Disorders

Volumn 8, Issue 4, 2010, Pages 355-363

  Singh, Baljit K ^a,b   Singh, Amoolya ^c   Mascarenhas, Desmond D ^a,b  

^a Mayflower Organization for Research and Education   (United States)

^b Protigen Inc   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANEPHRIL; CREATININE; HUMANIN; INSULIN; INSULIN RECEPTOR SUBSTRATE 2; NEPHRILIN; PHOSPHOTRANSFERASE; PROTEIN KINASE C; SGK1 ENZYME; STREPTOZOCIN; UNCLASSIFIED DRUG;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN;

ALBUMINURIA; AMINO ACID SEQUENCE; ANIMALS; BLOOD GLUCOSE; CARRIER PROTEINS; CELL LINE; CELL NUCLEUS; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOPRECIPITATION; INDICATORS AND REAGENTS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; MESANGIAL CELLS; MICE; MICE, INBRED DBA; MOLECULAR SEQUENCE DATA; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS;

EID: 77955590014     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2010.0011     Document Type: Article

References (20)

1. Abbott KC, Sanders LR, Bakris GL. Microalbuminuria in non- insulin-dependent diabetes mellitus. Implications for renal survival. Arch Intern Med 1994;154:146-153.
2. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes . N Engl J Med 1984;310:356-360.
3. Singh BK, Mascarenhas DD. Bioactive peptides control receptor for advanced glycated end product-induced elevation of kidney insulin receptor substrate 2 and reduce albuminuria in diabetic mice. Am JNephrol 2008;28:890-899.
4. Facchinetti V, Ouyang W, Wei H, Soto N, Lazorchak A, Gould C, Lowry C, Newton AC, Mao Y, Miao RQ, Sessa WC, Qin J, Zhang P, Su B, Jacinto E. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C . EMBO J 2008;27:1932-1943.
5. Garcia-Martmez JM, Alessi DR. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum-and glucocorticoid-induced protein kinase 1 (SGK1) . Biochem J 2008;416:375-385.
6. Woo SY, Kim DH, Jun CB, Kim YM, Haar EV, Lee SI, Hegg JW, Bandhakavi S, Griffin TJ, Kim DH. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling. J Biol Chem 2007;282:25604-25612.
7. Pearce LR, Huang X, Boudeau J, Pawlowski R, Wullschleger S, Deak M, Ibrahim AF, Gourlay R, Magnuson MA, Alessi DR. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J 2007;405:513-522.
8. Johnstone CN, Castellvi-Bel S, Chang LM, Sung RK, Bowser MJ, Pique JM, Castells A, Rustgi AK. PRR5 encodes a conserved pro- line-rich protein predominant in kidney: Analysis of genomic organization, expression, and mutation status in breast and col- orectal carcinomas. Genomics 2005;85:338-351.
9. Huq A, Singh B, Meeker T, Mascarenhas, D. The metal-binding domain of IGFBP-3 selectively delivers therapeutic molecules into cancer cells. Anti-Cancer Drugs 2009;20:21-31.
10. Singh B, Charkowicz D, Mascarenhas D. Insulin-like growth factor-independent effects mediated by a C-terminal metal- binding domain of insulin-like growth factor binding protein-3. J Biol Chem 2004;279:477-487.
11. Cavasin MA, Rhaleb NE, Yang XP, Carretero OA. Prolyl oli- gopeptidase is involved in release of the antifibrotic peptide Ac-SDKP. Hypertension 2004;43:1140-1145.
12. Breyer MD, Bottinger E, Brosius FC, Coffman TM, Harris RC, Heilig CW, Kumar Sharma K for the AMDCC. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2005;16:27-45.
13. Leong ML, Maiyar AC, Kim B, O'Keeffe BA, Firestone GL. Expression of the serum-and glucocorticoid-inducible protein kinase, Sgk, is a cell survival response to multiple types of environmental stress stimuli in mammary epithelial cells. J Biol Chem 2003;278:5871-5882.
14. Yang Q, Inoki K, Ikenoue T, Guan KL. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev 2006;20:2820-2832.
15. Lang F, Bohmer C, Palmada M, Seebohm G, Strutz-Seebohm N, Vallon V. Pathophysiological significance of the serum-and glucocorticoid-inducible kinase isoforms . Physiol Rev 2006;86: 1151-1178.
16. Cybulski N, Polak P, Auwerx J, Riiegg MA, Hall MN. mTOR complex 2 in adipose tissue negatively controls whole-body growth. Proc Natl Acad Sci USA 2009;106:9902-9907.
17. Jacinto E, Loewith R, Schmidt A, Lin S, Riiegg MA, Hall A, Hall MN. Mammalian TOR complex 2 controls the actin cytoskele- ton and is rapamycin insensitive. Nat Cell Biol 2004;6:1122-1128.
18. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, Mullholland DJ, Magnuson MA, Wu H, Sabatini DM. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009;15: 148-159.
19. Masri J, Bernath A, Martin J, Jo OD, Vartanian R, Funk A, Gera J. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res 2007;67:11712-11720.
20. Jackson JG, Zhang X, Yoneda T, Yee D. Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene 2001;20:7318-7325.